The authors also observed that the plasma level of the KRAS mutation (codon 12) decreased with CRT in all patients with no difference between responders and non-responders and that the higher MGMT promoter methylation status at baseline DNA was associated with a better tumor response. The gene discussed is KRAS; the disease is neoplasm.